Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Revvity said it had a strong start to the year, with growth in both Diagnostics and Life Sciences, including continued strength in reproductive health and improving immunodiagnostics outside China. Management also highlighted broad-based recovery across geographies and end markets, with academia and research performing well. The company pointed to the divestiture of its China immunodiagnostics business as a prior drag now being stripped out, which should support cash flow and growth visibility.

Analysis

This reads as an early-cycle inflection rather than a one-quarter beat: the mix is improving in both recurring consumables and higher-cycle academic/research demand, which is important because it suggests the recovery is not just price-driven or customer-stocking. The more interesting second-order effect is that a cleaner China exposure profile should reduce headline volatility and improve the market’s willingness to underwrite the multiple off global ex-China execution, especially if management can show the divested asset was dilutive to both growth and conversion. That can matter more than the lost revenue itself, because tools names often re-rate on perceived earnings quality before absolute growth inflects.

The main beneficiary is RVTY’s own equity profile: lower exposure to a structurally tougher geography should reduce the probability of surprise downdrafts in both organic growth and cash flow, which can support a tighter valuation band over the next 2-3 quarters. Competitively, this is modestly negative for peers still carrying heavier China diagnostics exposure, because Revvity is effectively choosing to trade away low-quality revenue for cleaner comparables and potentially better capital allocation. If the retained portfolio keeps broadening across end markets, the next leg is likely margin leverage from mix rather than a dramatic top-line breakout.

The key risk is that the recovery proves cyclical rather than secular: academia and research are notoriously sensitive to budget timing, so a 1-2 quarter improvement can stall quickly if funding or procurement normalizes. There is also execution risk from the divestiture itself — any loss of scale, stranded costs, or transition friction could offset the narrative benefit over the next 6-12 months. The catalyst to watch is the next two reporting periods: if ex-China growth and free-cash-flow conversion both improve simultaneously, the market will likely reward the simplification with multiple expansion; if not, this becomes a de-risking story rather than a growth story.

Key Decisions for Investors

• Long RVTY on pullbacks over the next 1-3 weeks; thesis is improved earnings quality plus lower China-related volatility, with upside from multiple expansion if the next 2 quarters confirm cleaner organic growth and FCF conversion.
• Use a RVTY / broader life-sciences-tools pair trade: long RVTY, short a peer with higher China diagnostics exposure, for 3-6 months; this isolates the rerating from geographic simplification rather than sector beta.
• Buy RVTY call spreads 3-6 months out if implied volatility is not elevated; structure for a 2:1 to 3:1 payoff on confirmation that divestiture removes a drag without impairing core growth.
• If the next update shows any sign of stranded-cost pressure or slower-than-expected cash conversion, trim 25-35% of the position quickly; the market will punish any hint that the divestiture was additive to growth but destructive to margin.